A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.
A federal judge declined to block mail prescriptions for the abortion pill mifepristone, at least temporarily, dealing a setback to Louisiana's effort to curtail access to the drug in states where abortion is banned.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The decision to deny blocking leaves the door open for a different outcome at a later date.
U.S. District Judge David Joseph, a Trump appointee sitting in Lafayette, Louisiana, refused Louisiana Attorney General Liz Murrill's request to pause FDA regulations from 2023 that allow mifepristone to be dispensed through the mail.1
Instead, Joseph granted the government's request to put the case on hold while an ongoing FDA safety review of the drug proceeds, ordering the agency to update the court on the status of its investigation within six months.1
The ruling is not a final decision. Joseph wrote that if the FDA fails to complete its review and make any necessary revisions within a reasonable timeframe, his analysis and the weight given to the relevant factors would change. He also said he believes the plaintiffs are likely to succeed on the merits of their case, a signal that the temporary pause should not be read as a vindication of the current access rules. Murrill said she would ask an appeals court to throw out the federal regulations, noting that the judge had acknowledged Louisiana suffers irreparable harm under the current rules.
Louisiana is one of 13 states that ban abortion at all stages of pregnancy. Murrill argues that allowing mifepristone to be mailed into the state undermines that ban and is separately pursuing criminal cases against doctors in California and New York accused of sending pills to patients in Louisiana, though neither state has agreed to extradite the physicians to face charges.1
Mifepristone, typically taken in combination with misoprostol, has become the central battleground in abortion access litigation since the Supreme Court's 2022 decision overturning Roe v. Wade.2
The drug's mail dispensing rules have been challenged in multiple jurisdictions. In 2024, the Supreme Court declined to block mail prescriptions in a separate case, though on the narrow grounds that the plaintiffs, anti-abortion doctors, lacked legal standing rather than on the merits of the underlying regulations.
The legal battles are playing out against a backdrop of rapidly changing abortion access patterns. One study found that by the end of 2024, one quarter of all abortions in the U.S. were accessed through telehealth, a fivefold increase in two years.1
A separate study found that in 2025, women in states where abortion is banned were more likely to obtain the drug through telehealth than by traveling to another state. Eight states have enacted laws protecting providers who prescribe abortion pills by telehealth and mail them into states with bans.
Abortion rights advocates stressed that Tuesday's ruling offers only temporary relief. Alexis McGill Johnson, president and CEO of Planned Parenthood Federation of America, said mifepristone and abortion access remain very much under attack from courts, the Trump administration, and state legislatures.
The FDA and the Department of Health and Human Services have separately announced they are reviewing the safety and efficacy of mifepristone, a process whose outcome could have significant implications for the drug's availability regardless of how the Louisiana case ultimately resolves.2
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
